

Steady Augmentation of Anti-Osteoarthritic Actions of Rapamycin by Liposome-Encapsulation in Collaboration with Low-Intensity Pulsed Ultrasound [Corrigendum]

Chen CH, Kuo SM, Tien YC, Shen PC, Kuo YW, Huang HH. *Int J Nanomedicine*. 2020;15:3771–3790.

The authors apologize for this error and advise it does not affect the results of the paper.

The authors have advised due to an error at the time of figure assembly, **Figure 2B** on page 3778 is incorrect. The correct **Figure 2** is shown below.




Figure 2 (A) Pure rapamycin at 20 nM decreased human normal chondrocyte proliferation by about 15% while (B) pure rapamycin and L-rapa with or without LIPUS did not cause significant effects on HOAC proliferation. (C) L-rapa at 20 nM and 2 nM in collaboration with LIPUS approximately doubled proteoglycan production in human normal chondrocytes cultured in alginate beads. (D) L-rapa at 2 nM alone and in combination with LIPUS increased type II collagen production by around 1.7-folds in human normal chondrocytes cultured in alginate beads (PG: proteoglycan; ** $P < 0.01$; *** $P < 0.001$; by one-way ANOVA, $N = 5$).